Chrysalis Formats Raja

BU Chrysalis 11 Points for Monthly
Annual Month:
1 Name H.Q Target 17-
18 L/Y Sales Tgt Sales
0 Total 0.0 0.0 0.0 0.0
Performance of Direct reportee's

Annual Month:
No of ASM Name/H.Q Target 17-
0 Total 0.0 0.0 0.0 0.0
Month
3 Brand Perf Rs Value Annual Target 17-18 16-17 Units
for the Month TGT
Units Value Units Value
A.S.V.S. 10 ml Liquid
Albumin 20% 100ml
Albumin 5%
Amphomul 50 Mg (different brand)
Asvs Lypho
Berirab P 2ml
Equirab 1500 iu
Histoglob 3 Vial
Polymyxin B (different brand)
SILVER STREAM 100ML
SILVER STREAM 250ML
Tetglob 1000 iu
Tetglob 250 iu
Tetglob 500 iu
Thromboflux 15 Lacs iu
Tropinin
U-Frag 500000 iu
Ulinase
Zoonovac Injection 1 X 1 Vial
Total 0.0 0.0
Total Power Brand 0 0.0 0.0 0.0 0.0
YTD Performance
YTD
4 Annual Target 17-18 16-17 Units
Brand Perf Rs Value TGT
YTD
Albumin 20% 100ml
Albumin 5%
Asvs Lypho
Berirab P 2ml
Equirab 1500 iu
Histoglob 3 Vial
SILVER STREAM 100ML
SILVER STREAM 250ML
Tetglob 1000 iu
Tetglob 250 iu
Tetglob 500 iu
Tropinin
U-Frag 500000 iu
Ulinase
Total Power Brands 0.0 0.0
Month:May-17 Month:YTD May'17

5 Expiry
L/y Exp Rs Exp Total Sales % to sales L/y
Total #DIV/0!
Receiveables more than 30 days Collection details

6 Plan Next
O/S As on April 1 Mth YTD Month
Total 0.0 0.0
Month YTD
Education/CME &
7 Annual Budget Budget Exp % Budget
Conf.
Total #REF! #REF! #REF! #REF! #REF!
Value Performance ASE/BDE/BDM-MONTH

8 Analysis (ASM Wise) No.s On Tgt 80-99% 60-79% Below 60%
Total 0 0 0 0 0
Vacancy Status
10 ASE Mangers
Zone
Budget Actual Vacancy Budget Actual
Total
Dr's Calls Actual Dr

11 MSL Coverage (ASM WISE) Dr in MSL Dr Met % Plan No.s Calls
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
Total 0 0 #DIV/0! 0 0
11 Points for Monthly Report Month 2
Month: YTD:
% Ach Gr YPM L/Y Sales Tgt Sales % Ach Gr
#DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0! 0.0 0.0 0.0 #DIV/0! #DIV/0!
Month: YTD:
Month:
Pri Plan next 3 months units
Ach - Primary Seceondary % Ach Primary Unit Growth
Units Value Units Units Value Month 1 Month 2
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
0.0 #DIV/0!
0.0 0.0 0.0 #DIV/0!
YTD
% YTD Annual
Units Value Units Units Value Units Value
0.0 #DIV/0! #DIV/0!
0.0 0.0 0.0 #DIV/0!
Month:YTD May'17
Rs Exp Total Sales % to sales
#DIV/0!
YTD % YTD to
Annual
Exp % budget
#REF! #REF! #REF!
YTD
No.s On Tgt 80-99% 60-79% Below 60%
0 0 0 0 0
Mangers H.Q/Designati
H.Q ASE on Managers
Vacancy ASE
% Dr Calls
met
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
% YTD Analysis Plan of Action
YPM Annual
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!

YPM Annual
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
Analysis Plan of Action

next 3 months units
Month 3


Annual Month:
0 Total 0.0 0.0 0.0 0.0
Performance of Direct reportee's

Annual Month:
No of ASE Name/H.Q Target 17-
0 Total 0.0 0.0 0.0 0.0
Month
3 Brand Perf Rs Value Annual Target 17-18 16-17 Units
for the Month TGT
Albumin 20% 100ml
Albumin 5%
Asvs Lypho
Berirab P 2ml
Equirab 1500 iu
Histoglob 3 Vial
SILVER STREAM 100ML
SILVER STREAM 250ML
Tetglob 1000 iu
Tetglob 250 iu
Tetglob 500 iu
Tropinin
U-Frag 500000 iu
Ulinase
Total 0.0 0.0
YTD Performance
YTD
YTD
Albumin 20% 100ml
Albumin 5%
Asvs Lypho
Berirab P 2ml
Equirab 1500 iu
Histoglob 3 Vial
SILVER STREAM 100ML
SILVER STREAM 250ML
Tetglob 1000 iu
Tetglob 250 iu
Tetglob 500 iu
Tropinin
U-Frag 500000 iu
Ulinase

5 Expiry
Total #DIV/0!

6 Plan Next
Total 0.0 0.0
Month YTD
Education/CME &
7 Annual Budget Budget Exp % Budget
Conf.
Total #REF! #REF! #REF! #REF! #REF!
Value Performance ASE/BDE/BDM-MONTH

8 Analysis (ASE Wise) No.s On Tgt 80-99% 60-79% Below 60%
Total 0 0 0 0 0
Vacancy Status
10 ASE H.Q/Designa
tion
Zone H.Q ASE Managers
Budget Actual Vacancy ASE
Total
MSL Coverage (ASE Dr's Calls Actual Dr

11 Dr in MSL Dr Met %
WISE) Plan No.s Calls
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
Total 0 0 #DIV/0! 0 0
Month: YTD:
Month: YTD:
Month:
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
0.0 #DIV/0!
0.0 0.0 0.0 #DIV/0!
YTD
% YTD Annual
0.0 #DIV/0! #DIV/0!
0.0 0.0 0.0 #DIV/0!
Month:YTD May'17
#DIV/0!
YTD % YTD to
Annual
Exp % budget
#REF! #REF! #REF!
YTD
No.s On Tgt 80-99% 60-79% Below 60%
0 0 0 0 0
% Dr Calls
met
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
YPM Annual
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!

YPM Annual
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!

next 3 months units
Month 3


Annual Month:
0 Total 0.0 0.0 0.0 0.0
Month
3 Brand Perf Rs Value Annual Target 17-18 16-17 Units TGT
for the Month
Albumin 20% 100ml
Albumin 5%
Asvs Lypho
Berirab P 2ml
Equirab 1500 iu
Histoglob 3 Vial
SILVER STREAM 100ML
SILVER STREAM 250ML
Tetglob 1000 iu
Tetglob 250 iu
Tetglob 500 iu
Tropinin
U-Frag 500000 iu
Ulinase
Total 0.0 0.0
YTD Performance
YTD
YTD
Albumin 20% 100ml
Albumin 5%
Asvs Lypho
Berirab P 2ml
Equirab 1500 iu
Histoglob 3 Vial
SILVER STREAM 100ML
SILVER STREAM 250ML
Tetglob 1000 iu
Tetglob 250 iu
Tetglob 500 iu
Tropinin
U-Frag 500000 iu
Ulinase

5 Expiry
Total #DIV/0!

6 Plan Next
Total 0.0 0.0
MSL Coverage (ASE Dr's Calls Actual Dr

11 Dr in MSL Dr Met %
WISE) Plan No.s Calls
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
Total 0 0 #DIV/0! 0 0
Month: YTD:
Month:
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
#DIV/0! #DIV/0! #DIV/0!
0.0 #DIV/0!
0.0 0.0 0.0 #DIV/0!
YTD
% YTD Annual
0.0 #DIV/0! #DIV/0!
0.0 0.0 0.0 #DIV/0!
Month:YTD May'17
#DIV/0!
% Dr Calls
met
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
#DIV/0!
YPM Annual
#DIV/0! #DIV/0!
#DIV/0! #DIV/0!

next 3 months units
Month 3


P
ASM-1/ASE-1 ASM-2 ASM-3
Product ASP
PRI SEC Cls PRI SEC Cls PRI SEC Cls
A.S.V.S. 10 ml Liquid 365
Albumin 20% 100ml 3350
Albumin 5% 4396
Asvs Lypho 431
Berirab P 2ml 3500
Equirab 1500 iu 327
Histoglob 3 Vial 212
SILVER STREAM 100ML 1474
Tetglob 1000 iu 2255
Tetglob 250 iu 784
Tetglob 500 iu 1350
Thromboflux 15 Lacs iu 1705
U-Frag 500000 iu 1909
Zoonovac Injection 1 X 1 Vial 224
Total 0.0 0.0 0.0 0.0 0.0 0.0
PRI- SEC SALES - MAY'2017
ASM-4 ASM-5 ASM-6 ASM-7 ASM-8
PRI SEC Cls PRI SEC Cls PRI SEC Cls PRI SEC Cls PRI SEC
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

ASM-8 ASM-9 Total
Cls PRI SEC Cls PRI SEC Cls
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0.0 0.0 0.0 0 0 0
PRI- SEC PLAN - JUne'2017
ASM-M ASM-2 ASM-3 ASM-4 ASM-5
Product ASP
SEC PRI SEC PRI SEC PRI SEC PRI SEC
A.S.V.S. 10 ml Liquid 365
Albumin 20% 100ml 3350
Albumin 5% 4396
Asvs Lypho 431
Berirab P 2ml 3500
Equirab 1500 iu 327
Histoglob 3 Vial 212
Tetglob 1000 iu 2255
Tetglob 250 iu 784
Tetglob 500 iu 1350
Thromboflux 15 Lacs iu 1705
U-Frag 500000 iu 1909
Zoonovac Injection 1 X 1 Vial 224
Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
LAN - JUne'2017
ASM-5 ASM-6 ASM-7 ASM-8 ASM-9 Total
PRI SEC PRI SEC PRI SEC PRI SEC PRI SEC PRI
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0
Dr Conversion APRIL & MAY
ASE Name Dr Name Dr Converted in April Sec Sales/POB
Dr Conversion Plan-JUNE
ASM Name Dr Name Conversion Plan for the Product Sec sales Plan
Survey Formats
1) ASVS/Snake Bite potential
3) Other New Products Survey
Billing Plan
VIZAG-HQ VZM-HQ SRIKAKULRAJAHAMUN
Survey Formats
1) ASVS/Snake Bite potential 10
2) Troponin I 100
3) Other New Products SurveGIVEN
Billing Plan
1) ASVS keepin in mind the s 1000/ JUNE
2) Zoonovac Order Booking 200
Stocks and Sales Statement

Hard Copies YES/5
ASE Review Formats

MSL YES/171 DRS
Call Average 8.7/22DAYS
No of Calls they made Las 191
KAKNADA ANKAPALIMR. RAMBVIJ-2 GNT KHAMAM NLR TPT KDP
KNL ATP
Name of The Hospital Dr Name No of Snake Bite Avg Consumption of ASVS in Season
Avg Consumption of ASVS in off Season Brand Using

Chrysalis Formats Raja

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Chrysalis Formats Raja

Hochgeladen von

Copyright:

Verfügbare Formate

BU Chrysalis 11 Points for Monthly

0 Total 0.0 0.0 0.0 0.0

Performance of Direct reportee's

0 Total 0.0 0.0 0.0 0.0

Month:May-17 Month:YTD May'17

Receiveables more than 30 days Collection details

Value Performance ASE/BDE/BDM-MONTH

Dr's Calls Actual Dr

% YTD Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

0 Total 0.0 0.0 0.0 0.0

Performance of Direct reportee's

0 Total 0.0 0.0 0.0 0.0

Month:May-17 Month:YTD May'17

Receiveables more than 30 days Collection details

Value Performance ASE/BDE/BDM-MONTH

MSL Coverage (ASE Dr's Calls Actual Dr

% YTD Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

0 Total 0.0 0.0 0.0 0.0

Month:May-17 Month:YTD May'17

Receiveables more than 30 days Collection details

MSL Coverage (ASE Dr's Calls Actual Dr

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

Analysis Plan of Action

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Stocks and Sales Statement

ASE Review Formats

Das könnte Ihnen auch gefallen